Leap Therapeutics, a leading biotechnology company specializing in targeted and immuno-oncology therapeutics, is set to participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY. The event, scheduled for Tuesday, November 28, 2023, at 8:00 a.m. Eastern Time, will provide an opportunity for Leap Therapeutics to showcase its innovative developments in the field of cancer treatment.
During the fireside chat, Douglas E. Onsi, President and Chief Executive Officer of Leap Therapeutics, will discuss the company’s most advanced clinical candidate, DKN-01. This humanized monoclonal antibody targets the Dickkopf-1 (DKK1) protein and shows promising potential in treating esophagogastric, gynecologic, and colorectal cancers. Another notable development from Leap Therapeutics is FL-301, a humanized monoclonal antibody targeting Claudin18.2, which is being developed to combat gastric and pancreatic cancer.
To provide wider access, Leap Therapeutics will offer a live webcast of the fireside chat on the Investors page of their website, https://investors.leaptx.com/. Additionally, a replay of the event will be available for a limited time.
Leap Therapeutics is at the forefront of immuno-oncology research, with other preclinical antibody programs targeting Claudin18.2/CD137 and GDF15. By focusing on targeted therapies and immuno-oncology, the company aims to revolutionize cancer treatment and improve outcomes for patients.
For more information about Leap Therapeutics and their cutting-edge advancements, please visit their website at http://www.leaptx.com. Any public filings with the SEC can be accessed through EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
FAQs
1. What is Leap Therapeutics?
Leap Therapeutics is a biotechnology company that specializes in the development of targeted and immuno-oncology therapeutics.
2. What is DKN-01?
DKN-01 is Leap Therapeutics’ most advanced clinical candidate. It is a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein and is being developed for the treatment of esophagogastric, gynecologic, and colorectal cancers.
3. What is FL-301?
FL-301 is a humanized monoclonal antibody developed by Leap Therapeutics. It targets Claudin18.2 and is being investigated for its potential in treating gastric and pancreatic cancer.
4. How can I access the live webcast of the fireside chat?
The live webcast of the fireside chat can be accessed on the Investors page of Leap Therapeutics’ website at https://investors.leaptx.com/.
5. Where can I find more information about Leap Therapeutics?
You can find more information about Leap Therapeutics on their website at http://www.leaptx.com. Additionally, any public filings can be accessed through EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.